News - Research, sofosbuvir


Current filters:


Popular Filters

Gilead’s ledipasvir/sofosbuvir achieved 100% SVR12 among chronic hepatitis C patients in Japan

Gilead’s ledipasvir/sofosbuvir achieved 100% SVR12 among chronic hepatitis C patients in Japan


US anti-virals major Gilead Sciences has released strong top-line results from a Phase III clinical trial…

Anti-viralsBiotechnologyGilead SciencesJapanledipasvirRegulationResearchsofosbuvirSovaldi

Impressive data for once-daily sofosbuvir and ledipasvir treatment of HCV genotype 1


Strong results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational…

Anti-viralsBiotechnologyGilead SciencesledipasvirResearchsofosbuvirSovaldi

New drug combo cures toughest cases of hepatitis C, hints to future injection-free therapies


Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans…

Anti-viralsBristol-Myers SquibbdaclatasvirGilead SciencesPharmaceuticalResearchsofosbuvir

Gilead's 1st-qtr profits rocket 63% on 11% revenue rise; moves forward with hep C program


US biotech firm Gilead Sciences (Nasdaq: GILD) has reported that revenues for the first quarter of 2013…

Anti-viralsBiotechnologyFinancialGilead SciencesledipasvirResearchsofosbuvir

Enrollment in Gilead's ION-1 study continues following planned DSMB review


US HIV/AIDS and antiviral drugs specialist Gilead Sciences (Nasdaq: GILD) has provided a positive update…

Anti-viralsBiotechnologyGilead SciencesledipasvirResearchsofosbuvir

Gilead rises as sofosbuvir meets endpoints in Ph III hepatitis C study


US AID/HIV drug giant Gilead Sciences (Nasdaq: GILD) saw its shares rise 2.5% to $42.60 in morning trading…

Anti-viralsBiotechnologyGilead SciencesResearchsofosbuvir

Positive results from two Ph III Studies of Gilead's sofosbuvir for hepatitis C


US biotech firm Gilead Sciences (Nasdaq: GILD) has revealed positive top-line results from two Phase…

Anti-viralsBiotechnologyGilead SciencesResearchsofosbuvir

Gilead Sciences updates on hepatitis C development programs


US biotech firm Gilead Sciences (Nasdaq: GILD) presented several updates regarding its late-stage pipeline…

Anti-viralsBiotechnologyGilead SciencesGS-5885Researchsofosbuvir

Clinical briefs from Novartis, Gilead and AstraZeneca


Swiss drug major Novartis (NOVN: VX) has released new two-year results from the largest Phase III study…

ACZ885Anti-Arthritics/RheumaticsAnti-viralsAstraZenecaBiotechnologyCerticanGilead SciencesnaloxegolNeurologicalNovartisPharmaceuticalResearchsofosbuvir

Back to top